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Background: There is no clear consensus regarding systemic treatment of early-stage ovarian cancer (OC). Clinical
trials are challenging because of the relatively low incidence and good prognosis. Initial results of the International
Collaborative Ovarian Neoplasm (ICON)1 trial demonstrated beneﬁt in both overall survival (OS) and recurrence-free sur-
vival (RFS) with adjuvant chemotherapy. We report results of 10-year follow-up to establish whether beneﬁts are main-
tained longer term and discuss how this and other available evidence from randomised trials can be used to guide
treatment options regarding the need for, and choice of, adjuvant chemotherapy regimen.
Patients and methods: ICON1 recruited women with OC following primary surgery in whom there was uncertainty as
to whether adjuvant chemotherapy was indicated. Patients were randomly assigned to adjuvant or no adjuvant chemo-
therapy. Platinum-based chemotherapy was recommended and 87% received single-agent carboplatin. Analyses of
long-term treatment beneﬁts and interaction with risk groups were carried out. A high-risk group of women was deﬁned
with stage 1B/1C grade 2/3, any stage 1 grade 3 or clear-cell histology.
Results:With a median follow-up of 10 years, the estimated hazard ratio (HR) for RFS was 0.69 [95% conﬁdence interval
(CI) 0.51–0.94, P = 0.02] and OS 0.71 (95% CI 0.52–0.98, P = 0.04) in favour of chemotherapy. In absolute terms, there
was a 10% (60%–70%) improvement in RFS and a 9% (64%–73%) improvement in OS; the beneﬁt of chemotherapy
might be greater in high-risk disease (18% improvement in OS). Uncertainty remains about the optimal chemotherapy
regimen. The only randomised trial data available are from a subset of 120 stage 1 patients in ICON3 where the treatment
difference, comparing carboplatin with carboplatin/paclitaxel was estimated with relatively wide CIs [progression-free
survival HR = 0.71 (95% CI 0.39–1.32) and OS HR = 0.98 (95% CI 0.49–1.93)].
Conclusions: Extended follow-up from ICON1 conﬁrms that adjuvant chemotherapy should be offered to women with
early-stage OC, particularly those with high-risk disease.
Clinical trial numbers: ISRCTN11916376 for ICON1 and ISRCTN57157825 for ICON3.
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introduction
Early-stage ovarian cancer (OC) comprises about 20% of all
cases of OC [1]. The prognosis of early-stage disease is signiﬁ-
cantly better than late-stage disease, with 5-year survival varying
from 80%–93% (stage 1/2) to <30% (stage 3/4) [2–5]. There is
no clear consensus regarding systemic treatment of early-stage
OC in terms of the need for, and choice of, adjuvant chemother-
apy regimen; these questions are however critical for women
with early-stage OC, aiming to maximise cure while minimising
treatment toxicities. Clinical trials in this setting are challenging
because of the relatively low disease incidence and good progno-
sis (requiring long follow-up).
In the 1990s, two trials [International Collaborative Ovarian
Neoplasm (ICON)1 and ACTION] were conducted to address
the uncertain survival beneﬁt of immediate adjuvant chemo-
therapy in early-stage disease [6, 7]. The primary analysis of
ICON1, with a median follow-up of 4 years demonstrated a
signiﬁcant improvement in both recurrence-free survival (RFS)†FC and WQ contributed equally as joint ﬁrst authors.
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[hazard ratio (HR) = 0.65, 95% conﬁdence interval (CI) 0.46–
0.91, P = 0.01] and overall survival (OS) (HR = 0.66, 95% CI
0.45–0.97, P = 0.03) in favour of immediate adjuvant chemo-
therapy [7]. Very similar ﬁndings were reported in the ACTION
trial [6]. We present here the 10-year follow-up results of
ICON1 to investigate whether the initial reported beneﬁts were
maintained in longer term and to explore whether the effect of
immediate adjuvant chemotherapy was different based on a stra-
tiﬁcation for risk of disease recurrence [8] (classiﬁed according
to tumour stage and tumour grade) with a larger number of RFS
and OS events observed from the longer follow-up.
When immediate adjuvant chemotherapy is used in early-
stage OC, the choice of optimal chemotherapeutic regimen
remains unclear. We provide an extensive discussion with a sys-
tematic review of randomised, controlled trials of adjuvant
chemotherapy including women with early-stage OC to explore
evidence for the effect of combination chemotherapy, or treat-
ment intensiﬁcation, in early-stage OC.
methods
patients
ICON1 was an international randomised phase III trial, started in 1991.
Patients with histologically conﬁrmed epithelial OC were eligible if, in the
opinion of the treating physician, there was uncertainty as to whether the
patient required immediate adjuvant chemotherapy. Patients had to be ﬁt to
receive chemotherapy, with no previous malignant disease (excepting non-
melanomatous skin cancer) and to have not received any previous chemo-
therapy or radiotherapy. The surgical requirements were that all visible
tumour had to be removed, but recommending minimally total hysterec-
tomy, bilateral salpingo-oophorectomy and omentectomy, consistent with
standard practice at that time. Ethical approval of the local institution and
written informed consent for all patients were required.
treatment
Patients were randomly assigned with a 1:1 ratio to receive immediate adju-
vant chemotherapy or no immediate adjuvant chemotherapy. Six cycles of
chemotherapy with either single-agent carboplatin (87% of patients
received) or the three-drug combination cyclophosphamide, doxorubicin
and cisplatin (CAP) was recommended, although alternative platinum-based
regimens were also allowed. No patients received paclitaxel. The planned
chemotherapy regimen for a patient was speciﬁed before individual random-
isation. Further details of the doses recommended are provided in the origin-
al publication [7].
long-term follow-up
ICON1 pre-speciﬁed follow-up to continue for RFS and OS to investigate
whether the long-term beneﬁt of adjuvant chemotherapy was maintained
and to explore any differential effect based on recurrence risk [8]. Women
were classiﬁed as low risk (stage 1A grade 1), intermediate risk (stage 1A
grade 2 or stage 1B/1C grade 1) and high risk (stage 1B/1C grade 2/3 and
any stage 1 grade 3 or clear cell histology) (Table 1). This was pre-speciﬁed
before the dataset lock for analyses and based on a review of published data,
clinical consensus and taking into account the distribution of patients
(without reference to outcomes) to have the most power from a comparison
of roughly equal groups (low/intermediate risk versus high risk). Survival
follow-up information was cross-checked with the UK Ofﬁce of National
Statistics and Italian Vital Statistics Ofﬁces.
statistical analysis
The primary outcome measure was OS, deﬁned as time from randomisation
to death from any cause. The secondary outcome measure was RFS, deﬁned
as the time from randomisation to clinically deﬁned recurrence or death
from any cause. Kaplan–Meier curves of RFS and OS were compared using
the standard log-rank test. Flexible parametric models [9] were applied for
estimating difference of RFS and OS between two arms overtime. A χ2 test
for interaction between treatment allocation and risk groups was carried out
for both RFS and OS outcome measures. All analyses were carried out on an
intention-to-treat basis and all statistical tests were two sided.
results
Between August 1991 and January 2000, 477 women (241 im-
mediate adjuvant chemotherapy, 236 no immediate adjuvant
chemotherapy) with epithelial OC were recruited from 84
centres in ﬁve countries. Patient characteristics were well
balanced between the two arms for accrual country, age, tumour
stage, residual bulk of disease, degree of tumour differentiation
and histological subtype. Figure 1 shows the ICON1 CONSORT
diagram. Full details of the chemotherapy administered are pro-
vided in the original publication [7].
The median follow-up is now 10 years with a total of 165
(35%) women who have developed disease recurrence or died
(71 adjuvant chemotherapy, 94 no adjuvant chemotherapy).
Comparison of Kaplan–Meier curves for RFS gives an estimated
HR = 0.69 (95% CI 0.51–0.94, P = 0.02) (Figure 2A). This trans-
lates into a 10% RFS improvement from immediate adjuvant
chemotherapy at 10 years, from 60% to 70%. The absolute dif-
ference of RFS and 95% CI of the difference between immediate
adjuvant therapy over no immediate adjuvant therapy over time
is displayed in Figure 2C.
A further 48 women have died, giving 151 (32%) deaths in
total (66 adjuvant chemotherapy, 85 no adjuvant chemother-
apy). Seventy-two percent of all deaths were attributed to OC.
Comparison of Kaplan–Meier curves (Figure 2B) gave an esti-
mated HR = 0.71 (95% CI 0.52–0.98, P = 0.04) in favour of im-
mediate adjuvant chemotherapy, translating into a 9% OS
improvement at 10 years, from 64% to 73%. The absolute differ-
ence of OS from immediate adjuvant therapy over no immediate
adjuvant therapy over time is displayed in Figure 2D.
The effect of immediate adjuvant chemotherapy in stage 1
patients (n = 428) by recurrence risk was explored (Table 1,
Figure 2E for RFS and Figure 2F for OS). The beneﬁt of immediate
adjuvant chemotherapy appears greatest in women with high-risk
stage 1 disease. In these women, for RFS the HR = 0.48 (95% CI
Table 1. Classiﬁcation of stage 1 patients by risk of recurrence
Grade 1 (%) Grade 2 (%) Grade 3 (%)
Stage 1A 13 20 10
Stage 1B 3 4 4
Stage 1C 15 17 12
Figures represent the proportion of patients in ICON1 (2%
unknown). Light grey represents low risk (13%); medium grey
represents intermediate risk (38%); dark grey represents high risk
(47%).
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0.31–0.73, P < 0.001) equates to an improvement at 10 years of
23% (95% CI 11% to 33%) from 45% to 68%. For OS in these
women, the HR = 0.52 (95% CI 0.33–0.81, P = 0.004) translates
into an 18% (95% CI 7% to 27%) improvement at 10 years, from
56% to 74%. In the low/intermediate-risk groups, for RFS, the
HR = 0.92 (95% CI 0.52–1.64, P = 0.78) equates with a 2% (95%
CI −13% to 12%) improvement at 10 years from 73% to 75%; for
OS the HR = 0.91 (95% CI 0.49–1.69, P = 0.77) gives an improve-
ment at 10 years of 2% (95% CI −12% to 11%) from 78% to 80%.
The tests for interaction for RFS (P = 0.075) and OS (P = 0.15)
suggest a different size of effect between the high-risk versus low/
intermediate-risk groups, but the trial was not powered for testing
such an interaction.
choice of chemotherapeutic regimen in early-stage
OC
A systematic literature search was carried out to identify phase III
trials of systemic ﬁrst-line adjuvant therapy (see supplementary
Appendix, available at Annals of Oncology online). Apart from
the ICON1 and ACTION trials, only four reported analyses relat-
ing to early-stage disease [10–13]. No evidence of a beneﬁt was
shown in early-stage OC with respect to treatment intensiﬁcation
by increasing dose density [12] or by adding a third drug [11] or
maintenance paclitaxel [13]. It is acknowledged that patient
numbers were small within the trials not speciﬁc to early-stage
OC. Only one study speciﬁcally informs the duration of standard
therapy in early-stage OC (GOG157) [10]; this trial compared
three versus six cycles of carboplatin/paclitaxel. No evidence of a
difference in RFS or OS was shown, although increased toxicity
occurred with six cycles.
In clinical practice, both carboplatin and carboplatin/pacli-
taxel are used in early-stage OC. No prospective randomised
clinical trials have directly compared carboplatin and carbopla-
tin/paclitaxel in this setting; however, data were available from
120 stage 1 patients enrolled into the ICON3 trial [14] (supple-
mentary Appendix, available at Annals of Oncology online).
Early-stage ovarian cancer - clinician uncertain whether
chemotherapy required
Immediate platinum-based
chemotherapy
n=241
Chemotherapy delayed
until indicated
n=236
Data frozen in Dec 2001 for publication
median follow up 51 months
185 (77%) alive no recurrence
14 (6%) alive with recurrence
8 (3%) dead without recurrence
33 (14%) dead after recurrence
1 (<1%) dead, no information on
recurrence
4 (2%) dead, no information on
recurrence
157 (67%) alive no recurrence
18 (8%) alive with recurrence
18 (8%) dead without recurrence
42 (18%) dead after recurrence
1 (<1%) dead, no information on
recurrence
5 (2%) dead, no information on
recurrence
Data frozen in April 2007
median follow up 10 years
166 (69%) alive no recurrence
9 (4%) alive with recurrence
17 (7%) dead without recurrence
45 (19%) dead after recurrence
137 (58%) alive no recurrence
14 (6%) alive with recurrence
22 (9%) dead without recurrence
58 (25%) dead after recurrence
Figure 1. International Collaborative Ovarian Neoplasm trial (ICON1) proﬁle. Patients were randomly assigned (1:1) into either immediate adjuvant chemo-
therapy arm or no immediate adjuvant chemotherapy arm.
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These data show a trend towards improved progression-free
survival (PFS) in favour of carboplatin/paclitaxel (HR = 0.71,
95% CI 0.39–1.32, P = 0.28) (Figure 3A) but no evidence of a dif-
ference in OS between the arms (HR = 0.98, 95% CI 0.49–1.93,
P = 0.94) (Figure 3B).
discussion
These updated data from ICON1 conﬁrm the long-term RFS
and OS beneﬁt from adjuvant platinum-based chemotherapy
in women with early-stage OC. Results are consistent with
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Figure 2. Updated ICON1 results with median follow-up 10 years.
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previous trials and a meta-analysis [7, 15–17]. The magnitude of
beneﬁt appears greatest in women with high-risk disease, which
indicates that chemotherapy should be standard of care in these
patients. A small beneﬁt in women with lower risk disease
cannot be excluded, and chemotherapy should be discussed,
considering individual patient and disease characteristics
including cyst rupture, age and histological subtype [18–20].
The choice of the optimal adjuvant chemotherapy regimen
and the duration of treatment in early-stage OC is a subject
of continuing debate. There were no treatment-related deaths
in ICON1, but cytotoxic chemotherapy can have potentially
serious and/or long-term complications [21], which are
increased when taxanes are added to platinum-based therapy. In
clinical practice, both carboplatin and carboplatin/paclitaxel are
used in this setting, although there is no clear evidence base to
support the use of combination therapy. Single-agent carbopla-
tin was the chemotherapy most frequently used in ICON1 and
ACTION and thus was the treatment recommended in ﬁrst
reports of these trials. The retrospective analyses comparing
carboplatin with carboplatin/paclitaxel using the 120 stage 1
patients in the ICON3 trial lead to wide CIs in the estimates of
treatment difference. Some will argue that the HR of 0.71 for
PFS, despite the wide CIs, supports the use of carboplatin/pacli-
taxel, whereas others will argue that the HR of 0.98 for OS and
increased toxicities with doublet therapies supports the use of
single-agent carboplatin. However, in the absence of any pro-
spective comparative randomised trials in this setting, with
observed estimated HR of 0.98 in OS, we support the use of less
toxic single-agent carboplatin. Further evidence for carboplatin
alone comes from a small retrospective study which demon-
strated no evidence of a difference in OS between carboplatin
and carboplatin/paclitaxel [22]. There was also no evidence
from the trials identiﬁed in the systematic review supporting
treatment intensiﬁcation (Table 2).
ICON1 was a pragmatic trial aligned with routine clinical
practice at the time, designed to include patients in whom the
indication for adjuvant chemotherapy was uncertain, and
without mandating speciﬁc disease staging. Because of this,
there has been comment that there was an unknown proportion
of patients with non-optimally surgically staged disease, who
could have had undetected more advanced disease [23]. While
this is true, even 15 years after ICON1 was started, delivering
optimal staging surgery in women with early-stage OC remains
a challenge. An incidental diagnosis of OC is still made in some
women following laparotomy or laparoscopy carried out for
expected benign disease and staging is often incomplete [24].
ICON1 remains the largest trial ever carried out in early-stage
OC and remains relevant. It is unlikely that trials in this setting
of this size will be repeated. The long-term follow-up of ICON 1
provides important conﬁrmatory results that aid decision
making by clinicians treating women with early-stage OC.
The updated results of ACTION trial [17] concentrate on a
retrospective subgroup analysis investigating the effect of imme-
diate adjuvant chemotherapy in patients optimally surgically
staged and those non-optimally surgically staged. They claim to
demonstrate a beneﬁt only in non-optimally surgically staged
patients, while the number of RFS and cancer-speciﬁc survival
events (36 and 19, respectively) in the subgroup of optimally
surgically staged patients (n = 151) are very small. Using risk
group classiﬁed similar to the published risk stratiﬁcation [8],
however, it appeared in ICON1 that there was a greater beneﬁt
from chemotherapy in women with high-risk stage 1 disease. In
this subgroup at 10 years, the absolute RFS beneﬁt was 23% and
the absolute OS beneﬁt was 18%. In the low/intermediate-risk
groups, the beneﬁts seen were much smaller (2% for RFS and
2% for OS at 10 years). This type of exploratory analysis was not
possible in the ACTION trial as patients with lower risk disease
(grade 1 stage 1A/1B) were excluded. In our opinion, given the
initial and long-term follow-up results of ICON1, the ACTION
subgroup analyses do not provide sufﬁcient evidence to exclude
any beneﬁt in optimally staged patients and should not lead to
immediate adjuvant chemotherapy being withheld from opti-
mally staged patients with early-stage OC.
In conclusion, the beneﬁt of adjuvant postoperative chemo-
therapy for early-stage OC is conﬁrmed with long-term follow-up
of ICON1, and it appears that the magnitude of beneﬁt is greatest
in patients with features that place them at a higher risk of recur-
rence. The use of single-agent carboplatin is recommended.
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Figure 3. Stage 1 patients randomised to carboplatin versus paclitaxel + carboplatin in ICON3 trial.
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Table 2. Summary of published studies of adjuvant chemotherapy in ovarian cancer allowing inclusion of patients with early-stage disease (I and/or IIA) and with available (ICON3) or reported (others)
early-stage analyses
Study Number Eligibility % Control arm Research arm No. of
cycles
Recruit HR
I II III/IV
ICON1 [7]
2003
477 Uncertain of beneﬁt from
chemotherapy
93 6 1 Observation Platinum based (most
carboplatin/CAP)
6 08/91-04/00 Overall OS
HR = 0.71, 95% CI 0.52–0.98,
P = 0.04
ACTION
2010 [18]
448 Ia–Ib, grade II–III; all stages Ic
and IIa, and all stages I–IIa
with clear-cell
93 7 0 Observation Platinum based 6 11/90-01/00 Overall CSS
HR = 0.73, 95% CI 0.48–1.13,
P = 0.16
ICON3 [14] 2074 FIGO stage I–IV 9 11 80 Carboplatin AUC5 ‘or’
Cyclophosphamide
500 mg/m2
Doxorubicin 50 mg/m2
Cisplatin 50 mg/m2
Paclitaxel (175 mg/m2, 3 h)
Carboplatin AUC5
6 02/95-10/98 Stage I OS
HR = 0.98, 95% CI 0.49–1.93,
P = 0.94
GOG157 [10] 427 FIGO stage Ia/b grade 3, clear
cell, Ic and completely
resected stage II
69 31 0 Paclitaxel (175 mg/m2, 3 h)
Carboplatin AUC 7.5
[3 cycles]
Paclitaxel (175 mg/m2, 3 h)
Carboplatin AUC7.5
[six cycles]
3 versus 6 03/95–05/98 Overall RFS
HR = 0.761, 95% CI 0.51–1.13,
P = 0.18
AGO-OVAR/
GINECO/NSGO
[11]
1742 All 8 10 82 Paclitaxel (175 mg/m2, 3 h)
Carboplatin AUC5
Paclitaxel (175 mg/m2, 3 h)
Carboplatin AUC5
Gemcitabine 800 mg/m2
day 1/day 8
6 2002–2004 Stage I/IIAOS
HR = 3.28, 95% CI 0.89–12.11,
P = 0.06 (in favour of standard
arm, but events scarce)
JGOG [12] 631 FIGO ≥stage II 0 18 82 Paclitaxel (175 mg/m2, 3 h)
Carboplatin AUC6
Paclitaxel (80 mg/m2 day
1, 8, 15)
Carboplatin AUC6
6 04/03-12/05 Stage II PFS (n = 116)
HR = 0·81, 95% CI 0·36–1·82
GOG-175 [13] 542 FIGO stage 1A/B grade 3/clear
cell or 1C/II
72 28 0 Paclitaxel (175 mg/m2, 3 h)
Carboplatin AUC6
Paclitaxel (175 mg/m2, 3 h)
Carboplatin AUC6
followed by Paclitaxel
(40 mg/m2, 1 h) q1w
6
24 weeks
09/98-12/06 All RFS
HR = 0.81, 95% CI 0.57–1.15
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